Document Detail

Effects of lecithin-emulsified perfluorochemical compounds in ischemic brain injury.
MedLine Citation:
PMID:  8055099     Owner:  NLM     Status:  MEDLINE    
A lecithin-emulsified "Pluronic F-68"-free perfluorochemical compound, named F-1,3-DMA, was tested as a new agent in the prevention of central nervous tissue ischemia. A permanent ischemia leading to cerebral infarction was induced after microsurgical exposure and occlusion of the internal carotid, anterior, and middle cerebral arteries in the rabbit. Following arterial occlusion, F-1,3-DMA was administered intravenously, in a solution rendered isotonic to plasma, over a 30 minute period. The F-1,3-DMA was well tolerated. Hemodynamic, cardiovascular and metabolic parameters were not affected by the infusion of F-1,3-DMA. Although PO2 remained virtually unchanged, animals treated with F-1,3-DMA (n = 9), had smaller infarct volume by 61 percent as compared to the control (n = 8) group (P < 0.04, Student's t-test). Histopathology did not reveal any F-1,3-DMA related damage in the non-infarcted brain. These results suggest that F-1,3-DMA has nervous tissue ischemia protective properties possibly because of microflow effects although O2 transport to "local" tissue may be enhanced as well. We believe that further research is necessary in order to make clinical trials of F-1,3-DMA possible.
D E Sakas; R M Crowell; N T Zervas
Related Documents :
7982029 - Morphological picture in paroxysmal nocturnal hemoglobinuria. case report.
18757219 - Cerebral infarction and neurodevelopmental outcome in childhood tuberculous meningitis.
6725429 - Neurologic deficit and cerebral atp depletion after temporary focal ischemia in cats.
1343859 - Frontal signs following subcortical infarction.
10797179 - Early exclusive use of the affected forelimb after moderate transient focal ischemia in...
16002219 - Hydroxysafflor yellow a protects rat brains against ischemia-reperfusion injury by anti...
9457009 - Prospective association between lipid soluble antioxidants and coronary heart disease i...
6607319 - Operative findings on microsurgical exploration of the cerebello-pontine angle in trige...
24663289 - A prediction model for 5-year cardiac mortality in patients with chronic heart failure ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Artificial cells, blood substitutes, and immobilization biotechnology     Volume:  22     ISSN:  1073-1199     ISO Abbreviation:  Artif Cells Blood Substit Immobil Biotechnol     Publication Date:  1994  
Date Detail:
Created Date:  1994-09-12     Completed Date:  1994-09-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9431307     Medline TA:  Artif Cells Blood Substit Immobil Biotechnol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  83-9     Citation Subset:  IM    
Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adamantane / analogs & derivatives*,  therapeutic use
Biological Transport / drug effects
Brain Ischemia / blood,  physiopathology,  prevention & control*
Cerebral Infarction / blood,  physiopathology,  prevention & control*
Hemodynamics / drug effects
Oxygen / blood
Reg. No./Substance:
0/Emulsions; 0/Phosphatidylcholines; 281-23-2/Adamantane; 36481-20-6/fluoro-1,3-dimethyloadamantane; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  FT-IR of membranes made with alginate/polylysine complexes. Variations with the mannuronic or guluro...
Next Document:  Inclusion of ganglioside GM1 into liposome encapsulated hemoglobin does not extend circulation persi...